Τίτλος:
Advances in the treatment of soft tissue sarcoma: Focus on eribulin
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Eribulin mesylate is a synthetic derivative of halichondrin B isolated from a marine sponge. Its mechanism of action is through microtubule inhibition, which is different from that of taxanes. Eribulin has been approved for the treatment of metastatic breast cancer and more recently for non-operable or metastatic liposarcoma in patients who have received prior anthracycline chemotherapy. The major side effects of eribulin are bone marrow suppression including neutropenia, leukopenia, anemia, and fatigue/weakness, which can be well managed. In this article, we reviewed evidence from the latest published data on eribulin and its use in the treatment of soft tissue sarcomas. We explored the drug’s mechanism of action, pharmacodynamics, pharmacokinetics, and metabolism. Lastly, we reviewed all preclinical studies as well as clinical trials that investigated eribulin. © 2018 Koliou et al.
Συγγραφείς:
Koliou, P.
Karavasilis, V.
Theochari, M.
Pollack, S.M.
Jones, R.L.
Thway, K.
Περιοδικό:
Cancer Management and Research
Εκδότης:
Dove Medical Press Ltd
Λέξεις-κλειδιά:
dacarbazine; eribulin; protein bcl 2; protein bcl xl; protein mcl 1, alopecia; anemia; antiangiogenic activity; antiproliferative activity; apoptosis; bone marrow suppression; drug clearance; drug dose escalation; drug dose reduction; drug efficacy; drug elimination; drug safety; drug structure; drug withdrawal; elimination half-life; epithelial mesenchymal transition; fatigue; febrile neutropenia; human; hypokalemia; leiomyosarcoma; leukopenia; liposarcoma; lymphocytopenia; maximum tolerated dose; metastatic breast cancer; microtubule assembly; mitosis inhibition; multiple cycle treatment; nausea; neutropenia; nonhuman; overall survival; pharmacodynamics; progression free survival; recommended drug dose; Review; sensory neuropathy; soft tissue sarcoma; solid malignant neoplasm; synovial sarcoma; thrombocytopenia; weakness
DOI:
10.2147/CMAR.S143019
